- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.12. | Editas axes two-thirds of its staff, including its CMO | ||
| 13.12. | Safety fear halts Keros PAH trial dosing, hitting its shares | ||
| 13.12. | Carlyle backs Essential refinancing and other funding news | ||
| 12.12. | NIH abandons trial of SIGA's mpox drug | ||
| 12.12. | Why is colorectal cancer rising in younger age groups? | ||
| 12.12. | Lynparza boosts long-term survival in early breast cancer | ||
| 12.12. | Price deal opens door to NHS use of Santhera DMD drug | ||
| 11.12. | Lilly adds another sales channel for obesity drug Zepbound | ||
| 11.12. | Mulvany hits the reset button at BenevolentAI | ||
| 11.12. | Refiling for cALD therapy on the cards after new data | ||
| 11.12. | Drug-digital dual therapy for depression starts phase 2 | ||
| 11.12. | Bausch + Lomb dips on rumour of failing takeover talks | ||
| 11.12. | uniQure rockets on map to market for Huntington's therapy | ||
| 10.12. | ASH: Stem cell transplant study exposes US zip-code lottery | ||
| 10.12. | ConTIPI starts rollout of pelvic organ prolapse device in US | ||
| 10.12. | MSD gets first positive trial of Keytruda/Lynparza combo | ||
| 10.12. | ASH: Blenrep ups survival by 42% in multiple myeloma trial | ||
| 10.12. | Suspect in UnitedHealth CEO killing charged with murder | ||
| 09.12. | Fresh from IPO, obesity drug developer BioAge hits a hurdle | ||
| 09.12. | ASH: Regeneron plays its PNH hand | ||
| 09.12. | ASH: MSD's ROR1 drug hits the target in first-line lymphoma | ||
| 09.12. | Novo's $16.5bn Catalent deal cleared by EU Commission | ||
| 09.12. | Relief for Chinese biotechs as BIOSECURE Act delayed | ||
| 06.12. | Lilly invests another $3bn in its manufacturing network | ||
| 06.12. | GSK builds neuro, cancer pipeline with trio of deals |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
